Guidelines - BIOTRONIK CardioMessenger Smart Manual Tecnico

92

Guidelines

8 Guidelines
Guidelines8399229-FTechnical ManualCardioMessenger ® Smart
Europe
Your device transmits diagnostic data to the Cardio-
Messenger via a radio frequency (RF) assigned by the
European Conference of Postal and Telecommunications
Administration for the operation of Ultra Low Power
Active Medical Implants (CEPT/ERC REC 70-03).
BIOTRONIK is legally obligated to inform you that the
radio service does not have exclusive use of the assigned
frequencies and that the transmission of device data is
not permitted to interfere with other radio services. The
frequency and technical parameters of the built-in trans-
mitter have been carefully selected to ensure that inter-
ference between other services and the data transmis-
sion of the device is unlikely.
Furthermore, BIOTRONIK is obligated to inform you that
the regulatory agency can withdraw the frequency alloca-
tion and prohibit the radio service between the device and
CardioMessenger. Since this service is currently estab-
lished throughout Europe and North America, withdrawal
of the frequency allocation is not expected in the foresee-
able future.
The CardioMessenger, like the implantable device itself,
has been evaluated by an independent testing authority
for its compliance with statutory regulations. The Cardio-
Messenger carries the following approval mark:
0681
0123 2015